Patent ID: 8957067
Filing Date: 2015-02-17
Classification: A61K,A61P

Abstract:
1. A method for treating Attention Deficit/Hyperactivity Disorder comprising: administering a first drug product comprising a first drug substance wherein said first drug substance comprises a first amine containing pharmaceutically active compound selected from the group consisting of methyl phenidate, amphetamine and imipramine and said first drug substance is at a first dose to reach a first therapeutic level of said first drug substance wherein said first drug substance has an immediate release profile of said first amine containing pharmaceutically active compound from said first drug substance wherein said immediate release profile is defined as at least 85% release within 30 minutes at gastric conditions; monitoring results of said first dose to determine second dose; administering a second drug product comprising said first drug substance at said second dose to reach a second therapeutic level wherein said second drug substance comprises said first amine containing pharmaceutically active compound with said immediate release profile; monitoring results of said second dose to confirm suitability of said second dose; administering a third drug product comprising a second drug substance wherein said second drug substance has a release profile which is slower than said immediate release profile and said slower release profile is suitable for maintaining said therapeutic level and said second drug substance is selected from the group consisting of: amorphous racemic-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic racemic-methylphenidate stearylamine pamoate characterized by at least one method selected from the group consisting of: amorphous d-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic d-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic racemic-methylphenidate pamoate characterized by at least one method selected from the group consisting of: amorphous dextro-amphetamine pamoate characterized by at least one method selected from the group consisting of: polymorphic dextro-amphetamine pamoate characterized by at least one method selected from the group consisting of: amorphous d-methylphenidate mono-triethylammonium pamoate characterized by at least one method selected from the group consisting of: amorphous imipramine mono-triethylammonium pamoate characterized by an PXRD diffractogram of polymorphic imipramine stearylamine pamoate characterized by at least one method selected from the group consisting of: amorphous imipramine, CH